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Abstract
Platelet-rich plasma (PRP) products can be described as any autologous blood platelet 
concentrate within a plasma suspension. PRP products include plasma and twofold or 
greater increases in platelet concentrations above baseline levels. The injection of acti-
vated PRP in its liquid formulation delivers growth factors locally and simultaneously 
mimics and amplifies the spontaneous healing response in injured areas and in special 
cell niches, which would otherwise be inaccessible. This in situ generated transient three-
dimensional scaffold will gradually release growth factors and maintain their concentra-
tion at the site of the scaffold formation. The combination of liquid PRP with surgical 
techniques in orthopaedic surgery allows a wide range of therapeutic strategies in the 
management of injuries in the field of orthopaedics and sports medicine. The use of dif-
ferent therapeutic elements, including PRP as biological stimuli and rehabilitation and 
physiotherapy treatments as mechanical stimuli, provides extremely favourable syner-
gies that will help fulfil the physician’s objective, to stop the progression of disease and 
to improve function in the shortest period of time
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1. Introduction
Virtually, all the cells of the musculoskeletal tissues are mechano-sensive and experience 
mechanical stress through the distortion of the extracellular matrix (ECM) complex. The 
exposure of musculoskeletal cells to nonphysiological stimuli, either mechanical or biochemi-
cal, leads to swings of the tissue pendulum towards profound alterations of components of 
the ECM both cellular and acellular as well as the physical and chemical properties of the 
ECM. Such stimuli lead to cell microenvironment damage, non-resolving inflammation and 
disease. In addition to specific features of each tissue (vascularization, innervation and type of 
cells), abnormal biomechanical loading as obesity, a sedentary lifestyle leading to metabolic 
disorders, joint injury or high intensity and prolonged sports activities make musculoskeletal 
tissues vulnerable to injury. Through such overuse or disuse, these nonphysiological stimuli 
may well produce a consequential disruption in tissue homeostasis (Figure 1).
A new innovative approach to the treatment of acute and chronic sports injuries uses engineer-
ing biology assisted by the application of platelet-rich plasma (PRP) in its different formula-
tions. Generally, PRP products can be described as any autologous blood platelet concentrate 
within a plasma suspension. PRP products include plasma and twofold or greater increases 
in platelet concentrations above baseline levels: not insignificantly, their concentration of leu-
kocytes and erythrocytes varies widely [1] from a complete absence of these cells to a high 
concentration of them. In this chapter, the described PRP has a platelet concentration between 
Figure 1. Both an excess and insufficiency of physical activity associated with factors such as vascular imbalance, 
intrinsic hereditary risk factors and a novel environment may disrupt the fragile homeostasis maintained by the tenocyte, 
stromal fibroblast and tissue-resident macrophages. A localised, predominantly catabolic context associated with a 
high temperature, ECM fragments and acidosis with building up of lactic acid may be the root cause of inflammation-
degeneration of the ECM.
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2- and 2.5-fold higher than blood and no leukocytes (PRGF®-Endoret®, BTI-Biotechnology 
Institute, Vitoria-Gasteiz) [2]. PRP can be activated with CaCl
2
 offering a variety of autolo-
gous formulations whose versatility endows this technology with a myriad of applications in 
orthopaedics [3–5].
This chapter addresses the following questions: Why would surgeons want to harness the bio-
logical features of PRP in the operating theatre? When are PRP injections indicated as an adju-
vant to? How should the injections be introduced to obtain beneficial outcomes in surgery?
2. Reasons to use PRPs as repair process enhancers in orthopaedic 
surgery: the scientific rationale behind it
The physicochemical features of PRP liquid formulation, once activated, make it appropriate 
to reach wide areas of soft and hard tissues such as the tendons, muscles, ligaments, menisci, 
cartilage and bone. Platelet growth factors and fibrin, together with plasmatic growth factors 
(HGF, IGF-1) present within PRP, stimulate in a pleiotropic manner cell proliferation and 
migration, angiogenesis, synthesis and deposition of ECM components and tissue remodel-
ling in the musculoskeletal tissues [6–8]. The surgical site is opened in the normal manner, and 
in the following 2: 4 minutes, the liquid-activated formulation must be injected as a solution 
into soft tissues. Because of its local and gradual activation and homogeneous distribution 
and interaction with the ECM of different tissues, it is converted into a matrix-like malleable 
transient structure [2]. There is a direct interplay between components of a tissue’s ECM (col-
lagens, glycosaminoglycans and adhesive proteins) and the adhesive proteins and growth 
factors released gradually from the degrading fibrin clot which will influence cellular growth, 
differentiation and morphogenesis [9]. Therefore, the injection of PRP in its liquid formula-
tion delivers growth factors locally and simultaneously mimics and amplifies the spontane-
ous healing response in injured areas and in special cell niches, which would otherwise be 
inaccessible. This in situ generated and moulded plastic nano-scaffold of fibrin interacts with 
ECM proteins and cells, binding to fibronectin [10], generating a transient three-dimensional 
scaffold, which will gradually release growth factors and maintain their concentration at the 
site of the scaffold formation (Figure 2)
The fibrin molecules, together with growth factors, influence and govern the repair mech-
anisms to reconstruct structures and restore function, both by harnessing local or resident 
cells and by stimulating cell migration and proliferation, thereby regulating angiogenesis, 
modulating inflammation, chemoattracting circulating progenitor cells and guiding tissue 
remodelling [11, 12]. PRP in situ generated nano-scaffold of fibrin offers a biologically active 
cell-matrix landscape where adhesive proteins, namely, fibrinogen, fibronectin, vitronectin 
and thrombospondin (TSP-1), facilitate cell adhesion, migration, proliferation and differen-
tiation. Furthermore, by the release of stromal cell-derived factor 1 (SDF-1) which has been 
entrapped in the fibrin network, the nano-scaffold mediates the chemotaxis of CD34 progeni-
tor cells and mesenchymal stem cells (MSCs) [7, 13, 14]. Once recruited, MSCs or pericytes 
[15] adhere to a fibrin network and may exert several functions such as tissue organisation, 
regulating the fate of other circulating and resident progenitor cells [16] and serving as 
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Figure 2. PRP niche therapy approach: injectable dynamic scaffold for molecular intervention.
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progenitor cells that replace the damaged tissue, prevent scar-forming cells from entering the 
damaged area and exerting immunomodulation activities [7, 14].
3. The use of PRP infiltrations in orthopaedics: surgical applications
Although it is not within the scope of this chapter to address the wide range of therapeutic 
strategies in the management of injuries in the field of orthopaedics and sports medicine, 
only a holistic approach will fulfil the objective of surgeons, namely, to stop the progression 
of disease and to improve function in the shortest period of time. In this respect, and as a 
clinical application of cell mechanotransduction, a rehabilitation programme, which included 
the employment of PRP in a synergistic manner would play a crucial role in both promot-
ing the repair or remodelling of injured tissue and avoiding the degradation and atrophy of 
structures such as the bone, periarticular muscles, tendons and ligaments with the goal of full 
recovery of function [17].
3.1. PRP infiltrations in tendon surgery
There is increasing evidence showing that tendon and ligament adaptation, injury and repair 
processes share several intracellular pathways, and although it is difficult to draw the line 
between the cellular and molecular responses that lead to either tissue adaptation or tissue 
damage, inflammatory processes appear to be at the interface of tendon adaptation and dam-
age [18–20]. Repetitive mechanical loading, as is the case in early stages of tendinopathy, 
and tendon overuse induce the activation of NF-κB in stromal fibroblasts and thereby the 
synthesis of matrix metalloproteinases (MMPs), two isoforms of cyclooxygenase (COX)-1 and 
COX-2 and PGE2 by inflammatory tenocytes and stromal fibroblasts, mast cells and other 
immunocompetent cells [18, 21–23]. PGE2 is a major systemic and local inflammatory media-
tor that decreases the production of collagen and causes aberrant differentiation of TDSCs 
into adipogenic and osteogenic lineages [23], which might partially account for the presence 
of fibrocartilage, calcifications and adipose tissue in injured and chronic degenerative tendons 
[18, 23, 24].
An excellent series of in vitro and in vivo studies demonstrated that blood-derived BDDT 
induced tenocyte proliferation, stimulated the synthesis of type I collagen and neovascular-
ization [9] and promoted differentiation of TDSCs into active tenocytes, but, significantly, the 
addition of leukocytes into the releseate increased the synthesis of PGE2 and the gene expres-
sion of MMP-1, MMP-13 and IL-1β and decreased the expression of alfa-SMA as a marker 
of active tenocytes. Among the myriad mediators conveyed by blood-derived BDDT, HGF 
and lipoxin A4 (LX4) have been shown to exert an anti-inflammatory and pro-resolution of 
inflammation effect on injured tendons [21–23].
3.1.1. Surgical treatment of acute ruptures of tendons
In the case of tendons such as the Achilles, patellar or quadricipital, the volume of blood 
extracted is approximately 60–70 mL (six to nine tubes). Blood is taken a few minutes prior 
to surgery, before any fluid or drugs are administered to the patient, in the operating theatre 
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itself. PRP should be prepared, while the patient is being prepared in the operating theatre 
and applied by injection immediately after activation ex vivo (Figure 2).
The injury site is accessed via a medial approach [25], the hematoma is evacuated and the 
necrotic tissue is debrided. Then, the tendon is repaired using non-reabsorbable material pre-
viously soaked in liquid-activated PRP. The PRP liquid freshly activated is infiltrated into the 
healthy tendon and the tendon/bone repair zone. Both the repair zone and the proximal and 
distal end stumps are injected (Figure 3). The use of small syringes means that large pres-
sures are exerted on the ECM of the tissue during infiltration. We therefore recommend the 
use of 10 mL Luer lock-type syringes with 21G needles. Upon infiltration, the needle should 
be oriented as closely as possible parallel to, and longitudinal with, the tendon as possible for 
an optimal diffusion of PRP (Figure 3). Repair concludes with closure of the peritenon. The 
peritendinous regions are also infiltrated in order to recruit mesenchymal stem cells, pericytes 
and endothelial cells [15]. Approximately 12 mL of PRP is used during this phase. Before 
closing the overlying skin, the affected area is covered with a fibrin scaffold. Once closed, the 
subcutaneous tissue is irrigated with freshly activated PRP. An ultrasound examination of the 
Achilles tendon is performed in week 3, and, if healing problems, especially intratendon cyst 
formation, are detected, liquid-activated PRP is infiltrated under ultrasound guidance in the 
outpatient manner.
It is mandatory to coordinate and integrate functional recovery in light of the changes to 
biological mechanisms. Achieving a shorter immobilisation time allows physiotherapy to be 
speeded up because of the formation of a more efficient repair tissue [4, 25, 26].
The application to ruptures of major tendons at other sites follows the same methodology. 
The sequence in which the PRP liquid is applied is the same, with the volumes being varied 
in each individual case (Figure 3). Two maxims must always be followed: the use of suture 
systems and repair techniques that respect the tendon’s native biology as far as possible and 
the achievement of mechanically stable configurations that allow early rehabilitation.
3.1.2. Surgical treatment of chronic tendinopathy
In patients with a tendinopathy in whom conservative management, including percutaneous 
infiltration of PRP, has failed, surgery may be indicated [5]. This procedure, which is based on 
longitudinal tenotomy with removal of the area of failed healing response together with the 
application of PRP, is intended to remove the degenerative tissue, induce neovascularization 
and provide the tendon with a physical support and three-dimensional structure where local 
and neighbouring cells (e.g., from the paratendon) can proliferate and synthesise both blood 
vessels and ECM. We have summarised the process in the following steps (Figure 4):
1. The tendon injury sites are located and excised. Longitudinal tenotomies should be per-
formed throughout the whole thickness of the tendon in the same direction as the fibres. 
The aim of this process is twofold: to access the whole tendon in order to remove all the 
degenerative tissue and to generate a repair stimulus in the injured tendon.
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2. Liquid-activated PRP (8–10 mL) is then injected into the tendon fibres at both the excision 
site and the proximal and distal ends of the injury site following the procedure depicted 
previously for tendon ruptures.
3. Once the subcutaneous tissue has been closed, it is infiltrated with freshly liquid-activated 
PRP.
Figure 3. Injection at the site distal and proximal to the rupture in the direction of the tendon fibres (A, B). PRP is injected 
into the healthy tendon as well. To determine the effect of infiltration angle, and the size of syringe and diameter of 
the needle on the diffusion, PRP stained with methylene blue was injected in Achilles tendon of the sheep (C, D, E). 
The optimal diffusion of the PRP was obtained when the needle was oriented as closely as possible parallel to, and 
longitudinal with, the tendon. Complete rupture of the quadricipital tendon (F, G).
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3.1.3. Management of postsurgical Achilles tendon complications with PRP
PRP application in combination with surgery meets the criteria for treatment of major com-
plications from Achilles tendon rupture and repair, namely, versatility, biocompatibility, bio-
safety and efficacy. After having carefully cleaned the necrotic area, we proceeded to apply 
PRP. We injected 3 mL of the activated liquid both in the distal and proximal tendon stumps 
as well as in healthy areas of the tendon as described previously. In addition, the paratendon 
construct was richly injected with PRP. In one case, an autologous semitendinosus tendon was 
used to fill the Achilles tendon gap. Before the graft was anchored, we injected PRP liquid into 
the newly formed tissue (during week 3 after the first operation), among the tendon fibres of 
the graft and into the reconstructed tendon [27].
Figure 4. After having performed longitudinal scarifications in the tendon, liquid-activated PRP (8–10 mL) is injected 
into the tendon fibres at both the excision site and the proximal and distal ends of the damaged area (A–D). Infiltration 
of the subcutaneous tissue with freshly liquid-activated PRP (E).
Plasma Medicine - Concepts and Clinical Applications44
3.1.4. Surgical treatment of rotator cuff tears
The three factors that cause tissue damage of connective tissue in the musculoskeletal system 
coincide in the aetiology of rotator cuff injuries: (1) mechanical factors, (2) overuse-related 
micro−/macrotraumas and (3) the vascular decompensation inherent to this structure. Indeed, 
biopsies have shown a structure with a disproportionately low degree of vascularization and cel-
lularity for its high level of functional demands. This tissue undergoes constant demands where 
the cell phenotypes cannot adapt themselves to the high level of motor demands and where 
stroll fibroblasts are chronically activated. The commitment and fragility become even more evi-
dent in gliding tendons in which the part of the tendon that is in contact with the bone develops 
an avascular fibrocartilaginous tissue in response to the compression forces. During the surgery, 
we infiltrate approximately 8–10 mL of liquid-activated PRP, distributing it as follows [28]:
1. Into the body of the damaged and sutured tendon in order to promote a chemotactic and 
angiogenic effect in it.
2. Into the myotendinous junction, where the majority of healthy cells are present, and the 
subacromiodeltoid bursa, a likely source of multipotent cells.
3. Into the tendon/bone region and into the cancellous bone of the humerus in order to stimu-
late mesenchymal stem cells in the cancellous bone.
4. Finally, we inject a further 8–10 mL of the remaining PRP into the subacromial space in 
order to bathe the entire sutured region.
Rotator cuff injuries tend to have a poor prognosis as more than 50% of sutured tendons 
may not heal. This fact highlights the importance of strictly observing the PRP protocol. An 
ultrasound examination is performed at week 3 and week 6, and the tendon suture and sub-
acromial space are infiltrated again (8–10 mL of liquid-activated PRP).
3.2. PRP injections in cartilage diseases
In spite of advances in pharmacological and surgical techniques, the treatment of cartilage inju-
ries is still a challenge. Articular cartilage is a tissue that is remarkably resilient to compres-
sive and shearing forces. Yet, it is highly fragile to alterations of the synovial membrane and 
subchondral bone, two well-vascularized tissues from where systemic and local inflammation 
insults arise. These aggressions are mediated by pro-inflammatory cytokines and inflamma-
tory macrophages and synoviocytes, which damage articular cartilage as in the case of rheu-
matoid arthritis or osteoarthritis [29]. However, synovial membrane and subchondral bone are 
also the egress point and source of nutrients and MSCs for mounting a chondrogenic reparative 
response, which is driven by the recruitment and chemotactic homing of synovium and bone 
marrow-derived stem cells mediated by SDF-1, TGF-β and fibronectin. This is the case in micro-
fracture techniques and in the combinatorial strategy using intraarticular (IA) and intraosseous 
(IO) infiltrations of blood-derived BDDT such as PRP [30]. In doing so, PRP tackles the four 
synovial joint tissues and acts as a dynamic autologous liquid scaffold that, in a sustained and 
gradual manner, conveys chemotactic endogenous MSC homing and chondrogenic factors 
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such as SDF-1, TGF-β and fibronectin [31, 32]. In addition, PRP dampens inflammatory stress 
at the level of joint tissues, by both inhibiting the NF-κB on chondrocytes and macrophages 
[33] and upregulating the antioxidant response element NF-E2-related factor 2 (NrF2-ARE) 
pathway in osteoblasts [34]. Improvements of clinical outcomes of patients with knee and hip 
OA were reported applying this strategy [35, 36] which might primarily be mediated by HGF, 
CTGF, IGF-1 and PDGF, among others [33, 34, 37], thereby paving the way to cartilage regen-
eration; however, elusively, it remains.
3.2.1. PRP and chondral surgery
In joint diseases, the whole joint is affected: cartilage, subchondral bone, synovium, ligaments, 
neural tissue, etc. Thus, all components of the joint are essential to maintain homeostasis, and 
both genetic and acquired or environmental factors can break this balance, causing degen-
eration of cartilage, subchondral bone and other joint components and becoming a clinical 
problem [36]. The use of PRP as treatment in joint pathology is based on its capacity to restore 
homeostasis joint, to have inductive and protector effects on chondrocytes and to act on the 
synovial membrane, stimulating the production of hyaluronic acid and other molecules. All 
these properties contribute to the promotion of a biological environment that is conducive to 
slowing the joint cartilage degeneration and relieving clinical symptoms [37].
3.2.2. Fracture/avulsion and osteochondritis dissecans
The first step is to debride the wound bed and to separate the fragment carefully. The bony surface 
of the said fragment is refreshed to achieve an appropriate appearance. When a bleeding bed is 
obtained by spongialization, an intraosseous infiltration of 3 mL of liquid-activated PRP is con-
ducted. Next, the osteochondral fragment is fixed into its original niche and its stability is endured. 
Finally, 2 mL of PRP is infiltrated into space between the wound bed and the fragment using a fine 
needle. When the fragment is reinserted, the region around all edges is filled and sealed.
3.2.3. Osteochondral injuries with an inviable fragment
In this case, the subchondral bone is debrided removing all damaged tissue as in the osteo-
chondritis dissecans. Therefore, a spongialization is conducted in order to achieve a bleeding 
bed. The Pridie procedure or microfractures are performed to drill the bone, and a trocar is 
introduced in order to infiltrate liquid-activated PRP. Consequently, MSCs are stimulated, 
generating cell and molecular signals that promote the repair processes of joint cartilage. 
Moreover, a three-dimensional fibrin matrix is formed from PRP, which traps the cells that 
have come to the lesion area. As a result, the synthesis of the new tissue is promoted, perform-
ing a similar mechanical function as the original.
3.2.4. Extensive osteochondral injuries and necrosis
First, the injured tissue has to be debrided in order to achieve a bleeding spongy bone. Next 
microfractures are conducted and serum is aspirated by intraarticular wash. Finally, liquid-acti-
vated PRP is administrated by an intraosseous (3–5 mL) and an intraarticular (8 mL) injections.
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The use of autologous osteochondral grafts are recommended when subchondral bone is 
affected by osteonecrosis of the medial condyle of the knee. Infiltrations of liquid-activated 
PRP help to integrate such graft. These infiltrations are conducted into the bed and bone osteo-
chondral graft and in the interface where the allograft is implanted. At the end of surgery, 
serum is aspirated, intraarticular space washed and PRP infiltrated in an intraarticular man-
ner. During the post-operative period, three intraarticular injections of PRP are performed on 
a weekly basis. Initially, the patient has to walk assisted by crutches with minimal load.
3.2.4.1. Avascular osteonecrosis of the hip
This condition is the final point of several factors. Below, we describe the steps and times for 
this surgery and the use of PRP [37]. This arthroscopic protocol describes the “light bulb” 
technique and the biological support to achieve satisfactory results during a mean follow-up 
of 14 months (Figure 5).
1. Both diagnosis and treatment of associated intra-articular damages are addressed by 
arthroscopy.
2. During stages I and IIA, arthroscopic vision allows to perform several image-guided perfo-
rations in order to decompress the necrotic cephalic region. With a trocar, liquid-activated 
PRP is administrated into this region and into the surrounding healthy bone with it. When 
the femoral head is deformed, an osteoplasty is conducted and PRP infiltrated.
Figure 5. Arthroscopic diagnosis of associated damage. Creation of perforations down to the necrosis bed. Intraosseous 
infiltration with PRP.
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3. In stages IIA and IIB, where the condition curses with cystic and sclerotic changes, a de-
bridement and removal of necrotic tissue are performed with trephines, curettes and a 
synoviotome. When the healthy bone is available, autologous bone graft is impacted into 
the femoral in order to adapt it properly. The preparation of graft is carried out by using 
the ipsilateral iliac crest bone graft and liquid-activated PRP. When the size of the injury 
allows it, a demineralized bone matrix/PRP mixture can be applied.
4. Finally, 8 mL of liquid-activated PRP is injected into the joint. In the next weeks, infiltra-
tions are repeated (three or four times) under ultrasound guide.
3.3. PRP infiltrations in bone damage
When a fracture occurs, the first tissue-based phenomena to be manifested are tissue destruc-
tion, vessel rupture and cell necrosis. This results in bleeding that stimulates and activates 
defence systems to prevent excess bleeding and contamination of the injury site (both of 
which may be life-threatening). Although the fracture site tends to be hypoxic, with an altered 
pH and mechanical instability (the local reaction attempts to isolate the fracture site to pre-
vent infection), cells such as platelets, endothelial cells and macrophages are responsible for 
orchestrating a cell-based response by releasing growth factors such as PDGF, TGF-β, IGF I 
and IGF II, FGFs, VEGF, BMPs, IL-1, IL-6, TNF-α and PGE2 [38]. This group of bioactive mol-
ecules promotes the attraction/migration of osteogenic and MSCs from the periosteum and 
bone marrow, as well as fibroblasts from the surrounding soft tissue to the fracture site, where 
they form an extensive network based on fibrin and other plasma proteins.
These growth factors play a key role in the initial phases of recruitment/migration, MSC mito-
genesis and angiogenesis, which are essential. Simultaneously, the development of new blood 
vessels is stimulated and under the influence of angiogenic factors such as angiopoietin 1 and 
VEGF. MSCs and osteoprogenitor cells continue to express BMPs, which induce chondro−/
osteogenesis and ECM synthesis. These MSCs initially form aggregates that express tran-
scription factors sox9 and col2 (to express cartilaginous proteins) and then differentiate into 
chondroblasts (by the third or fourth day). The TGF-β expressed by both platelets and endo-
thelial cells during the initial stages of callus formation, and subsequently by chondrocytes 
and osteoblasts, appears to be key to both MSC chemotaxis and proliferation and the chon-
drogenesis and formation of endochondral bone [30, 39].
3.3.1. Treatment of fractures assisted with PRP
We have developed a set of basic guidelines for the application of PRP during the minimally 
invasive treatment of bone fractures (Figure 6) [5].
1. Once the whole context of the fracture has been assessed to determine the most appropri-
ate treatment, 36 mL of peripheral venous blood is withdrawn. Occasionally, due to the 
type of bone and fracture, it may be necessary to extract further amounts of blood.
2. Reduction and percutaneous osteosynthesis of the fracture under radiographic guidance. 
If the fracture does not require osteosynthesis, the process can be performed under radio-
graphic control ensuring optimal sterility.
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3. Liquid PRP is then activated for injection at the previously reduced and stabilised fracture 
site, under radiological control, to form the fibrin clot that is responsible for sustained re-
lease of the cell signals that induce the biological repair programme.
4. The volume of PRP infiltrated depends on the size of the fracture, although it is normally 
around 8 mL.
5. Healing of the fracture is then monitored clinically and radiographically. If signs of consol-
idation delay are detected, liquid PRP is injected a second time between weeks 4 and 6 in 
the same manner as the first infiltration (radiographic guidance and between 6 and 8 mL).
3.3.2. Surgical fracture treatment
Generally, irrespective of the type of osteosynthesis material expected to be used (always on 
the basis of the most appropriate surgical indication), this biological bone regeneration ther-
apy is used with PRP in either its liquid form or as a fibrin membrane or clot during surgical 
fracture repair. Our group has developed a set of basic guidelines for the application of PRP 
during the surgical treatment of fractures [5].
The fracture to be treated is assessed to determine the amount of PRP required and therefore the 
volume of blood to be extracted. If surgical treatment of the fracture site does not require the use 
of allo- or autografts, the fracture is reduced/stabilised. Sound stabilisation of the fracture site is 
a key factor in the subsequent repair process. Liquid-activated PRP is infiltrated at the fracture 
site and at its bony ends, using a Luer Lock syringe fitted with a needle of the appropriate gauge 
(Figure 7).
Figure 6. Infiltration of liquid PRP at the fracture site, after stabilisation, under radioscopic control: Colle’s fracture (A), 
Bennett’s fracture (B) and a distal finger/hand phalanx fracture (C, D).
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It is particularly important to stress that in the case of fractures of the fibula, calcaneus and other 
sites where the skin tends to heal poorly, we apply PRP on the skin margins of the surgical 
wound to enhance spontaneous epithelisation and to induce a bacteriostatic and anti-inflamma-
tory effect. If fracture repair presents signs of delayed consolidation, a further percutaneous infil-
tration is performed at the fracture site following the same basic steps as described previously.
3.3.3. Treatment of nonunions
When the nonunions present a stable fracture area and appropriate osteosynthesis, the pro-
cedure consists in a percutaneous infiltration under anaesthesia. It is important to locate and 
infiltrate the edges of the bones accurately by using an image amplifier. In these cases, a trocar 
is used to perform the injection to allow several controlled perforations in the injured site. 
The fracture region and contiguous bone areas are infiltrated with 6–8 mL of liquid-activated 
PRP. This treatment is repeated in a weekly basis up to a total of three infiltrations (Figure 8).
When an adequate fixation is not reached, debriding and bleeding of the bony edge fragments 
are conducted in the nonunion area. Next, the region is stabilised using appropriate osteosyn-
thesis material. Liquid-activated PRP is infiltrated into the edges of the bone fragments as in 
the previous case. When the nonunion presents a bone defect, a bone graft (auto- or allograft) 
is used together with liquid-activated PRP.
If the criteria described before are followed, treated patients should evolve favourably, pre-
senting clinical and radiographic results that show full resolution in between 2 to 6 months 
[40]. Similar outcomes have been achieved by other authors such as Seijas et al. [41].
Figure 7. Infiltration of liquid PRP at the fracture site, after stabilisation and osteosynthesis, into an olecranon fracture 
(A), into the os acromiale (B), into a fracture of the humeral head (C) and (D) at the radial fracture.
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3.4. PRP and meniscal surgery
The abundant ECM (between 60 and 70% of tissue weight) presented in meniscus deter-
mines the reparation of this tissue. Cells such as fibrochondrocytes and fibroblast are 
dispersed throughout the ECM. The peripheral area or meniscal wall presents the tissue 
vascularity (limited to 10: 30%), the largest number of cells, and it receives nerve endings 
[42]. Due to these characteristics, the recovery capacity of meniscus is highly influenced by 
this outer portion, since that is where the repair stimuli are generated [43]. Meniscus par-
ticipates in the stability to the knee and in the support of compressive, traction and shear-
ing forces. In addition, it absorbs part of the mechanical stress received by the knee and 
takes part in the lubrication of the knee. Thus, injuries in this structure compromise joint 
function, and it is recommendable to enhance its limited regenerative capacity to achieve 
an optimal repair. Because promising results are showed by PRP on meniscal cells in labo-
ratory experiments [44], it has been emerged as a novel technique for treating meniscal 
tears [45].
3.4.1. Meniscectomy
Bearing in mind the special conditions of the meniscal wall, liquid-activated PRP needs to 
be infiltrated into this structure during a partial meniscectomy. The injection is conducted 
in an extra-articular way (from outside to inside). However, when the posterior horn of the 
external meniscus is infiltrated, the injection is performed from inside to avoid vascular or 
nerve damage. A 21G needle and a 3 mL syringe are used in order to spread the PRP into the 
meniscus, since a high pressure is required because of the high density of this tissue com-
pared with other structures. Finally, an intraarticular infiltration is performed with 8 mL of 
liquid-activated PRP is infiltrated in an intraarticular manner.
The maintenance of the meniscal wall is a key element to achieve a partial repair and heal-
ing process of the meniscus, and it should be maintained whenever possible. This region pres-
ents the cellularity and vascularization needed to generate the biological stimuli for repair and 
regeneration.
Figure 8. Percutaneous infiltration of liquid-activated PRP at the area of a humeral nonunion (A) under radiological 
control (B).
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3.4.2. Meniscal sutures
The meniscal sutures are a suitable technique to preserve the structure of the knee and conse-
quently reach greater stability and protection of cartilage. The infiltration protocol is similar 
to that described in the meniscectomies, but in this case, PRP infiltration is applied not only 
into the meniscal wall but also into the suture region. An intraarticular infiltration of PRP is 
carried out when the whole process is finished. After 14 days other intraarticular injections of 
PRP could be conducted to improve the repair process, depending on the evolution of patient.
3.5. PRP in the management of neuropathies
PRP products hold an important therapeutic potential as a neuroprotective, neurogenic and 
neuroinflammatory therapeutic modulator system [46–50] and as enhancer of sensory and 
motor functional nerve-muscle unit recovery [51–53]. They are applied either as a filler of 
nerve conduits or vein-muscle grafts across nerve gaps post-trauma by ultrasound-guided 
perineural and intraneural infiltrations or as scaffolds to bridge or wrap the injured nerve 
stumps [54–56]. Moreover, there are non-traumatic peripheral injuries such as compression, 
adhesion and fibrosis [46], where this novel approach may diminish undesirable consequences 
such as fibrotic scars and denervated organ atrophy, since this adjuvant therapy can speed 
up the functional recovery of the nerve-muscle unit [55–58]. The therapeutic potential of PRP 
for nerve repair lies in the prolonged and gradual delivery system of biomolecules and in its 
function as a transient guidance scaffold for axonal sprouting [51, 57]. Considering Schwann 
cells (SC) as key in the nerve repair process, they are an idoneal target for the synergic action 
of neurotrophic and neurotropic factors of PRP. Thus, the release of biomolecules from the 
fibrin matrix at the beginning of regeneration process would induce several biological effects 
of SC aimed to repair [58–60].
In surgical repair by PRP as in the case of end-to-end neurorrhaphy, nerve compression and 
nerve entrapment, we recommend combining intraneural and perineural infiltrations of liq-
uid PRP with the application of a PRP membrane as scaffold, which wraps the injured tissue.
4. Guidelines for the appropriate use of PRP infiltrations
Good treatment commences with a correct overall diagnosis that entails the highest number 
of factors implicated in the disease and considers all the best options.
1. It should be remembered that inactivated PRP can be stored for 3–4 hours without losing 
its efficacy. However, once activated, it must be used immediately, in the ensuing 2–3 min-
utes after activation. This aspect provides us with room for manoeuvre when scheduling 
its use in the theatre room.
2. The volume of the infiltration syringe and the diameter of the needle used will affect the 
diffusion of PRP within the tissues. The use of small syringes means that large pressures 
are exerted on the ECM structures during infiltration, thereby accounting for local disrup-
tion of the components.
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3. Upon infiltration, the needle should be oriented as closely as possible, parallel to and lon-
gitudinal with the tendon. This results in the optimal diffusion of PRP while allowing the 
position of the needle to be controlled as closely as possible with ultrasound guidance.
4. The application of PRP should not alter the surgical technique commonly used for their 
repair. The main result of combining PRP with surgical treatment is to shorten and lessen 
the intensity of the initial defence phase and to accelerate the proliferative and trophic 
phases during the tissue repair process.
5. It is fundamental to combine the application of PRP with other rehabilitation treatments 
and physiotherapy as mechanical stimuli. Indeed, the combination of different therapeutic 
elements provides extremely favourable synergies.
6. Given the heterogeneous composition and products of PRPs, it is difficult to ascertain gen-
eral guidelines in order to optimise them. Rehabilitation and other systemic factors such 
as nutritional imbalance, overuse or disuse of tissues and life style may account for the 
majority of degenerative processes.
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